What do patients do during a familial Mediterranean fever attack? Their strategies and associated factors
- PMID: 40593432
- DOI: 10.1007/s11739-025-04039-6
What do patients do during a familial Mediterranean fever attack? Their strategies and associated factors
Abstract
Familial Mediterranean fever (FMF) is an autosomal recessive autoinflammatory disease characterised by recurrent fever and serositis. Despite colchicine's proven efficacy, attacks may persist, necessitating the implementation of various mitigation strategies by patients. To identify attack mitigation strategies and associated factors in FMF patients. A cross-sectional study at a tertiary rheumatology clinic included adults (≥ 18 years) meeting Tel-Hashomer criteria, on colchicine for ≥ 6 months, with ≥ 1 attack in the past six months. Patients were asked about their attack mitigation strategies, including colchicine dose increase, emergency department (ED) admission, resting, abdominal hot pack, dietary changes, on-demand anakinra, herbs, paracetamol, non-steroidal anti-inflammatory drugs (NSAIDs), and corticosteroid use. Among 258 patients (98 men, 160 women; median age 35 years, disease duration 18 years), 93% used mitigation strategies. The most common first choice was ED admission (19.8%), followed by colchicine dose increase (18.2%), resting (14.3%), dietary changes (4.3%), NSAIDs (7%), paracetamol (6.6%), on-demand anakinra (6.2%), herbs (6.2%), and corticosteroids (5%). Normal C-reactive protein (CRP) levels, shorter last attack duration, lower international Severity Score for FMF (ISSF), non-working and non-M694V mutations were linked with colchicine dose increase (p < 0.05). M694V positivity, working, persistent CRP elevation, dominant serositis and musculoskeletal attacks, education level ≤ 8 years, longer last attack duration, higher ISSF, current colchicine resistance and non-adherence were linked with ED admission (p < 0.05). Most FMF patients used strategies to mitigate attacks, mainly ED admission and colchicine dose increase. These were influenced by genetic mutations, attack type, working status, education, and CRP levels.
Keywords: Attack; Colchicine; Emergency department; Familial Mediterranean fever; Mitigating strategies.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Conflict of interest: All authors disclose no conflicts of interest. Ethical approval and consent to participate: The project received permission from the local ethics committee of the University of Health Sciences. Informed written consent was acquired from patients before enrollment. The study complied with the principles of the Declaration of Helsinki (date: 05.07.2023, decision number: 2023/165).
Similar articles
-
Interventions for reducing inflammation in familial Mediterranean fever.Cochrane Database Syst Rev. 2022 Mar 29;3(3):CD010893. doi: 10.1002/14651858.CD010893.pub4. Cochrane Database Syst Rev. 2022. PMID: 35349164 Free PMC article.
-
Efficacy and safety of treatments in Familial Mediterranean fever: a systematic review.Rheumatol Int. 2016 Mar;36(3):325-31. doi: 10.1007/s00296-015-3408-9. Epub 2015 Dec 19. Rheumatol Int. 2016. PMID: 26687683
-
Paracetamol (acetaminophen) or non-steroidal anti-inflammatory drugs, alone or combined, for pain relief in acute otitis media in children.Cochrane Database Syst Rev. 2023 Aug 18;8(8):CD011534. doi: 10.1002/14651858.CD011534.pub3. Cochrane Database Syst Rev. 2023. PMID: 37594020 Free PMC article.
-
Non-steroidal anti-inflammatory drugs (NSAIDs) for chronic non-cancer pain in children and adolescents.Cochrane Database Syst Rev. 2017 Aug 2;8(8):CD012537. doi: 10.1002/14651858.CD012537.pub2. Cochrane Database Syst Rev. 2017. PMID: 28770976 Free PMC article.
-
Colchicine for acute gout.Cochrane Database Syst Rev. 2021 Aug 26;8(8):CD006190. doi: 10.1002/14651858.CD006190.pub3. Cochrane Database Syst Rev. 2021. PMID: 34438469 Free PMC article.
Cited by
-
"What do patients do during a familial Mediterranean fever attack? Their strategies and associated factors: a critical appraisal.Intern Emerg Med. 2025 Jul 24. doi: 10.1007/s11739-025-04065-4. Online ahead of print. Intern Emerg Med. 2025. PMID: 40705218 No abstract available.
References
-
- Tekgöz E, Çolak S, Çınar FI, Yılmaz S, Çınar M (2021) Non-adherence to colchicine treatment is a common misevaluation in familial Mediterranean fever. Turk J of Med Sci 51(5):2357–2363. https://doi.org/10.3906/sag-2102-328 - DOI
-
- Kayacan Erdoğan E, Babaoglu H, Coşkun Ş et al (2025) Comorbidity profile of familial Mediterranean fever patients varies by treatments. Hitit Medical Journal. 7(1):53–60. https://doi.org/10.52827/hititmedj.1582847 - DOI
-
- Kisla Ekinci RM, Kilic KE, Akay N, Gul U (2024) Familial Mediterranean fever in childhood. Turkish archives of pediatrics 59(6):527–534. https://doi.org/10.5152/TurkArchPediatr.2024.24188 - DOI - PubMed - PMC
-
- Tufan A, Lachmann HJ (2020) Familial Mediterranean fever, from pathogenesis to treatment: a contemporary review. Turkish J Med Sci 50(SI-2):1591–1610. https://doi.org/10.3906/sag-2008-11 - DOI
-
- Yoshida S, Sumichika Y, Saito K et al (2023) Effectiveness of Colchicine or Canakinumab in Japanese patients with familial Mediterranean fever: a single-center study. J Clin Med 12(19):6272. https://doi.org/10.3390/jcm12196272 - DOI - PubMed - PMC
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous